These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
51 related articles for article (PubMed ID: 7909969)
1. Stable biological and antigenic characteristics of HIV-2SBL6669 in nonpathogenic infection of macaques. Zhang YJ; Putkonen P; Albert J; Ohman P; Biberfeld G; Fenyö EM Virology; 1994 May; 200(2):583-9. PubMed ID: 7909969 [TBL] [Abstract][Full Text] [Related]
2. Autologous neutralizing antibodies to SIVsm in cynomolgus monkeys correlate to prognosis. Zhang YJ; Ohman P; Putkonen P; Albert J; Walther L; Stålhandske P; Biberfeld G; Fenyö EM Virology; 1993 Dec; 197(2):609-15. PubMed ID: 7902628 [TBL] [Abstract][Full Text] [Related]
3. CD4-independent use of the CCR5 receptor by sequential primary SIVsm isolates. Laurén A; Vincic E; Hoshino H; Thorstensson R; Fenyö EM Retrovirology; 2007 Jul; 4():50. PubMed ID: 17645788 [TBL] [Abstract][Full Text] [Related]
4. Infected macaques that controlled replication of SIVmac or nonpathogenic SHIV developed sterilizing resistance against pathogenic SHIV(KU-1). Stephens EB; Joag SV; Atkinson B; Sahni M; Li Z; Foresman L; Adany I; Narayan O Virology; 1997 Aug; 234(2):328-39. PubMed ID: 9268165 [TBL] [Abstract][Full Text] [Related]
5. Broad cross-neutralizing activity in serum is associated with slow progression and low risk of transmission in primate lentivirus infections. Fenyö EM; Putkonen P Immunol Lett; 1996 Jun; 51(1-2):95-9. PubMed ID: 8811351 [TBL] [Abstract][Full Text] [Related]
6. Neutralizing antibody patterns and viral escape in HIV-1 non-B subtype chronically infected treatment-naive individuals. Kelly HR; Urbanski M; Burda S; Zhong P; Konings F; Nanfack J; Tongo M; Kinge T; Achkar J; Nyambi P Hum Antibodies; 2005; 14(3-4):89-99. PubMed ID: 16720979 [TBL] [Abstract][Full Text] [Related]
7. Induction of long-term protective effects against heterologous challenge in SIVhu-infected macaques. Villinger F; Switzer WM; Parekh BS; Otten RA; Adams D; Shanmugam V; Bostik P; Mayne AE; Chikkala NF; McClure HM; Novembre F; Yao Q; Heneine W; Folks TM; Ansari AA Virology; 2000 Dec; 278(1):194-206. PubMed ID: 11112494 [TBL] [Abstract][Full Text] [Related]
8. Sequential immunization of macaques with two differentially attenuated vaccines induced long-term virus-specific immune responses and conferred protection against AIDS caused by heterologous simian human immunodeficiency Virus (SHIV(89.6)P). Kumar A; Lifson JD; Li Z; Jia F; Mukherjee S; Adany I; Liu Z; Piatak M; Sheffer D; McClure HM; Narayan O Virology; 2001 Jan; 279(1):241-56. PubMed ID: 11145906 [TBL] [Abstract][Full Text] [Related]
9. Superinfection of HIV-2-preinfected macaques after rectal exposure to a primary isolate of SIVmac251. Wakrim L; Le Grand R; Vaslin B; Chéret A; Matheux F; Theodoro F; Roques P; Nicol-Jourdain I; Dormont D Virology; 1996 Jul; 221(2):260-70. PubMed ID: 8661436 [TBL] [Abstract][Full Text] [Related]
10. Identification of a window period for susceptibility to dual infection with two distinct human immunodeficiency virus type 2 isolates in a Macaca nemestrina (pig-tailed macaque) model. Otten RA; Ellenberger DL; Adams DR; Fridlund CA; Jackson E; Pieniazek D; Rayfield MA J Infect Dis; 1999 Sep; 180(3):673-84. PubMed ID: 10438354 [TBL] [Abstract][Full Text] [Related]
11. Chronology of genetic changes in the vpu, env, and Nef genes of chimeric simian-human immunodeficiency virus (strain HXB2) during acquisition of virulence for pig-tailed macaques. McCormick-Davis C; Zhao LJ; Mukherjee S; Leung K; Sheffer D; Joag SV; Narayan O; Stephens EB Virology; 1998 Sep; 248(2):275-83. PubMed ID: 9721236 [TBL] [Abstract][Full Text] [Related]
12. Neutralization escape in human immunodeficiency virus type 1-infected long-term nonprogressors. Bradney AP; Scheer S; Crawford JM; Buchbinder SP; Montefiori DC J Infect Dis; 1999 May; 179(5):1264-7. PubMed ID: 10191234 [TBL] [Abstract][Full Text] [Related]
13. Changing sensitivity to broadly neutralizing antibodies b12, 2G12, 2F5, and 4E10 of primary subtype B human immunodeficiency virus type 1 variants in the natural course of infection. Bunnik EM; van Gils MJ; Lobbrecht MS; Pisas L; van Nuenen AC; Schuitemaker H Virology; 2009 Aug; 390(2):348-55. PubMed ID: 19539340 [TBL] [Abstract][Full Text] [Related]
14. Human immunodeficiency virus-2 infection in baboons is an animal model for human immunodeficiency virus pathogenesis in humans. Locher CP; Barnett SW; Herndier BG; Blackbourn DJ; Reyes-Terán G; Murthy KK; Brasky KM; Hubbard GB; Reinhart TA; Haase AT; Levy JA Arch Pathol Lab Med; 1998 Jun; 122(6):523-33. PubMed ID: 9625420 [TBL] [Abstract][Full Text] [Related]
15. Development of virus-specific immune responses in SHIV(KU)-infected macaques treated with PMPA. Kumar A; Buch S; Foresman L; Bischofberger N; Lifson JD; Narayan O Virology; 2001 Jan; 279(1):97-108. PubMed ID: 11145893 [TBL] [Abstract][Full Text] [Related]
16. A minimally replicative HIV-2 live-virus vaccine protects M. nemestrina from disease after HIV-2(287) challenge. Looney DJ; McClure J; Kent SJ; Radaelli A; Kraus G; Schmidt A; Steffy K; Greenberg P; Hu SL; Morton WR; Wong-Staal F Virology; 1998 Mar; 242(1):150-60. PubMed ID: 9501043 [TBL] [Abstract][Full Text] [Related]
17. Autologous neutralizing antibodies prevail in HIV-2 but not in HIV-1 infection. Björling E; Scarlatti G; von Gegerfelt A; Albert J; Biberfeld G; Chiodi F; Norrby E; Fenyö EM Virology; 1993 Mar; 193(1):528-30. PubMed ID: 8438591 [TBL] [Abstract][Full Text] [Related]